Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on understanding the best treatment approaches of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Todd Bauer as the primary speaker and Dr. Ullas Batra as a moderator who will share the important facts associated with treatment approaches for management of ALK positive lung cancer.
Dr. Todd Bauer has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, a discussion on all possible treatment approaches and their pros, cons are discussed.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
Even when they are not paying attention, children are still learning.
4.
The Benefits of Exercise for Substance Use Disorders.
5.
The top three drugs for multiple myeloma treatment upfront are four.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
5.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation